Pharma BD Deal Intelligence
Lilly's ~$250M Mablink buy paid off: the PSARLink linker asset MB-1707, renamed sofetabart mipitecan, posted a ~55% ORR at ASCO 2025 in platinum-resistant ovarian cancer and won FDA Breakthrough Therapy Designation in January 2026, positioning it against AbbVie's Elahere.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly plans to acquire French antibody-drug conjugate developer Mablink Bioscience to bolster its oncology pipeline with a next-generation linker platform.…
Eli Lilly and Company has announced an agreement to acquire French biotech Mablink Bioscience, which specializes in next-generation antibody-drug conjugates…
FDA granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156, originated from Lilly's Mablink acquisition) for platinum-resistant epithelial…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Lilly acquired French ADC specialist Mablink Bioscience, gaining the PSARLink hydrophilic polysarcosine linker technology and lead candidate MB-1707 (a.k.a. MBK-103), an FRalpha-targeted exatecan ADC positioned as a next-generation rival to AbbVie's Elahere. Announced October 18, 2023; closed December 1, 2023. Deal terms undisclosed; press estimates ~$250M including milestones. Post-close the asset was renamed LY4170156 and received the INN sofetabart mipitecan. It advanced into a Phase 1a/b study (NCT06400472), with first clinical data at ASCO 2025 (June) showing a preliminary ORR of ~55% at the 4 mg/kg Q3W dose in platinum-resistant ovarian cancer, including responses in patients who had progressed on prior mirvetuximab soravtansine; updated data followed at ESMO 2025 (October). On January 20, 2026 the FDA granted sofetabart mipitecan Breakthrough Therapy Designation for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who received prior bevacizumab and mirvetuximab soravtansine, and the asset advanced into the Phase 3 FRAmework-01 program (NCT07213804). The original bolt-on thesis has been strongly validated.
20K US cases/yr · $8.0B Global ovarian cancer therapeutics market 2024 (USD MM) · 250 Press-estimated total deal size (USD MM, undisclosed by parties)
Folate receptor alpha (FR-alpha) is highly expressed in approximately 80% of epithelial ovarian cancers, 50% of endometrial cancers, and a subset of non-small cell lung cancers and triple-negative breast cancers, making it one of the most attractive ADC targets in solid tumor oncology. Ovarian cancer accounts for approximately 19,680 new US cases annually with 12,740 deaths (ACS Cancer Facts & Figures 2024); endometrial cancer adds 67,880 new US cases and 13,250 deaths. Most ovarian cancer patients are diagnosed at advanced stage and ultimately develop platinum-resistant disease, where five-year survival is under 30%. ImmunoGen's Elahere (mirvetuximab soravtansine-gynx), the first-in-class FR-alpha ADC, received FDA accelerated approval November 2022 and full approval March 2024 for platinum-resistant, FR-alpha-high ovarian cancer; ImmunoGen was acquired by AbbVie for $10.1B in February 2024, validating the target class commercially. Lilly's Mablink acquisition brings MB-1707, a second-generation FR-alpha ADC differentiated by the proprietary PSARLink hydrophilic linker enabling higher drug-antibody ratio (DAR 8) with improved solubility, stability and therapeutic index versus first-generation ADCs. Mablink's PSARLink is positioned as a platform applicable across multiple targets beyond FR-alpha.
The FR-alpha and next-generation ADC-linker landscape is intensifying. Approved FR-alpha ADC: Elahere (mirvetuximab soravtansine-gynx, AbbVie/ImmunoGen) — first-in-class, acquired by AbbVie for $10.1B February 2024; generated ~$160M Q4 2024 sales and ramping. FR-alpha clinical-stage ADCs: MB-1707 (Lilly/Mablink, PSARLink platform), STRO-002 luveltamab tazevibulin (Sutro Biopharma, Phase 2/3 REFRaME-O1 in platinum-resistant ovarian), farletuzumab ecteribulin (MORAb-202, Eisai/Merck, Phase 2 ovarian and endometrial), IMGN151 (AbbVie/ImmunoGen next-gen FR-alpha-low extension). Broader next-generation ADC linker platforms competing for partner-of-choice positioning include Daiichi Sankyo/AstraZeneca DXd (Enhertu, Datroway, patritumab deruxtecan, ifinatamab deruxtecan); Pfizer/Seagen vedotin (Padcev, Adcetris, Tukysa franchise); Merck/Kelun-Biotech Trop2 sac-TMT platform; Pfizer/Nurix Nectin4 successors; Bicycle Therapeutics BT1718 and BT5528 bicyclic-peptide-drug conjugates; Ambrx (acquired by J&J January 2024); Synaffix (acquired by Lonza 2023); LegoChem Biosciences ConjuAll (Carbon-Sulfur linker). PSARLink's differentiation is higher DAR (>=8) with hydrophilic shielding to mitigate aggregation and pharmacokinetic clearance penalties, potentially enabling payload-class flexibility (topoisomerase-I inhibitors, tubulin binders, PBD dimers) and reduced hepatotoxicity versus legacy SMCC and MC-VC linkers used in Kadcyla and earlier vedotin conjugates. The strategic prize is Lilly's ability to compete cross-target in the rapidly consolidating ADC space currently led by Daiichi/AstraZeneca and AbbVie.
LY4170156 / sofetabart mipitecan (formerly Mablink's MB-1707) showed a preliminary ORR of ~55% at 4 mg/kg Q3W in platinum-resistant ovarian cancer, including responses post-mirvetuximab. Phase 1a/b NCT06400472.
FDA granted BTD for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who received prior bevacizumab and mirvetuximab soravtansine. Asset now in Phase 3 FRAmework-01 (NCT07213804).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Mablink Bioscience SAS (this deal) | 2023 | $250M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2023 deals · Eli Lilly and Company deals · Oncology deals